Cost effectiveness of tissue plasminogen activator

Article Abstract:

Physicians may be less likely to use expensive treatments unless the treatment can be shown to be cost-effective. Studies have shown that tissue plasminogen activator (t-PA) can open coronary arteries blocked by a blood clot more quickly than streptokinase, but it is also much more expensive. A 1995 study found that the use of t-PA costs approximately $32,678 per year of life saved. Other cost-effectiveness studies have found much higher expenses for other treatments. For example, researchers found that treatment of high blood pressure could cost up to $72,100 per year of life saved. In the era of managed care, insurance companies may be likely to pay for an expensive treatment if it improves outcomes and reduces the need for re-hospitalization or long-term care. Expensive treatments may be more cost-effective if they are only given to those most likely to benefit.

Health aspects, Editorial, Analysis, Economic aspects, Medical care, Cost of, Health care costs, Tissue plasminogen activator, Thrombolytic therapy

---

A middle ground on public accountability

Article Abstract:

There is an argument for the collaboration among payers, purchasers, patients and providers in the development system of public accountability. Patients are given potential report cards with illnesses, which often gives inconsistent results.

Management dynamics, HEALTH SERVICES, Management, Evaluation, Health care industry, Patients, Patient care, Company business management

---

Similar abstracts:

• Abstracts: The continuing effectiveness of active management of first labor, despite a doubling in overall nulliparous cesarean delivery
• Abstracts: Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation
• Abstracts: Accurate detection of anomalies by routine ultrasonography in an indigent clinic population. Dilutional hyponatremia in preeclampsia with and without nephrotic syndrome
• Abstracts: A post-genomic perspective. Overexpression of heat-shock proteins reduces survival of Mycobacterium tuberculosis in the chronic phase of infection
• Abstracts: An attitude problem? RoSPA calls for tougher action on director code. Obstacle course, part 3

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.